Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purepac Glucophage XR ANDA Status Could Factor Into Injunction Ruling

Executive Summary

A D.C. federal judge's decision on whether Ivax should be preliminarily enjoined from immediately marketing its generic version of Glucophage XR could hinge on the imminent approvability of Purepac's ANDA for metformin extended-release

You may also be interested in...



Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days

Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications

Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days

Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications

Ivax Glucophage XR Generic Exclusivity Rights Questioned By Judge

FDA's rationale for awarding Glucophage XR generic marketing exclusivity to Ivax rather than Purepac received a skeptical hearing from a federal judge Nov. 12

UsernamePublicRestriction

Register

PS042849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel